Herbert Virgin Sells 3,805 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Herbert Virgin sold 3,805 shares of the firm’s stock in a transaction dated Tuesday, January 12th. The shares were sold at an average price of $29.36, for a total value of $111,714.80. Following the sale, the executive vice president now owns 37,005 shares in the company, valued at $1,086,466.80. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Herbert Virgin also recently made the following trade(s):

  • On Tuesday, December 22nd, Herbert Virgin sold 3,805 shares of Vir Biotechnology stock. The shares were sold at an average price of $31.19, for a total value of $118,677.95.
  • On Tuesday, December 8th, Herbert Virgin sold 3,805 shares of Vir Biotechnology stock. The shares were sold at an average price of $31.27, for a total value of $118,982.35.
  • On Friday, November 27th, Herbert Virgin sold 2,930 shares of Vir Biotechnology stock. The shares were sold at an average price of $30.00, for a total value of $87,900.00.
  • On Tuesday, November 24th, Herbert Virgin sold 2,340 shares of Vir Biotechnology stock. The stock was sold at an average price of $27.29, for a total value of $63,858.60.
  • On Tuesday, November 10th, Herbert Virgin sold 2,340 shares of Vir Biotechnology stock. The stock was sold at an average price of $26.26, for a total value of $61,448.40.
  • On Tuesday, October 27th, Herbert Virgin sold 3,805 shares of Vir Biotechnology stock. The stock was sold at an average price of $35.04, for a total value of $133,327.20.

Shares of Vir Biotechnology stock opened at $35.55 on Thursday. The stock has a market cap of $4.53 billion and a P/E ratio of -5.65. The stock’s 50 day simple moving average is $29.16 and its 200-day simple moving average is $31.40. Vir Biotechnology, Inc. has a 1-year low of $13.13 and a 1-year high of $75.00.

Vir Biotechnology (NASDAQ:VIR) last released its quarterly earnings results on Tuesday, November 10th. The company reported ($0.67) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.57) by ($0.10). The firm had revenue of $1.93 million for the quarter, compared to analysts’ expectations of $2.65 million. Vir Biotechnology had a negative net margin of 293.64% and a negative return on equity of 81.12%. As a group, research analysts forecast that Vir Biotechnology, Inc. will post -2.13 earnings per share for the current fiscal year.

Several equities research analysts recently issued reports on VIR shares. Zacks Investment Research cut Vir Biotechnology from a “hold” rating to a “sell” rating in a report on Saturday, December 12th. HC Wainwright lifted their price objective on Vir Biotechnology from $80.00 to $100.00 and gave the stock a “buy” rating in a report on Wednesday, October 7th. Robert W. Baird reiterated a “sell” rating and issued a $24.00 price objective on shares of Vir Biotechnology in a report on Friday, December 25th. BidaskClub cut Vir Biotechnology from a “hold” rating to a “sell” rating in a report on Wednesday, January 6th. Finally, Bank of America began coverage on Vir Biotechnology in a report on Monday, October 5th. They issued a “buy” rating and a $55.00 price objective on the stock. Three analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $52.50.

Hedge funds have recently added to or reduced their stakes in the company. Principal Financial Group Inc. purchased a new stake in shares of Vir Biotechnology during the 2nd quarter valued at approximately $1,286,000. Amalgamated Bank raised its position in shares of Vir Biotechnology by 12.4% during the 3rd quarter. Amalgamated Bank now owns 8,331 shares of the company’s stock valued at $286,000 after buying an additional 922 shares during the period. Profund Advisors LLC purchased a new stake in shares of Vir Biotechnology during the 3rd quarter valued at approximately $446,000. Trexquant Investment LP purchased a new stake in shares of Vir Biotechnology during the 3rd quarter valued at approximately $466,000. Finally, WINTON GROUP Ltd purchased a new stake in shares of Vir Biotechnology during the 3rd quarter valued at approximately $1,791,000. 41.50% of the stock is currently owned by hedge funds and other institutional investors.

About Vir Biotechnology

Vir Biotechnology, Inc, a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis.

Featured Article: Debt-To-Equity Ratio

Insider Buying and Selling by Quarter for Vir Biotechnology (NASDAQ:VIR)

Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.